Here are four things to know:
1. The company surpassed its goal of $1.5 million in the funding round.
2. The funding comes weeks before the company’s anticipated launch date for its magnesium-based bone void filler product, OsteoCrete.
3. OsteoCrete is resorbable, injectable, moldable, osteoconductive and nontoxic.
4. The FDA cleared the product for long-bone and general orthopedic applications.
More articles on devices:
Histogenics acquires sole development, marketing rights for NeoCart in Japan: 5 key notes
Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points
Medtronic invests in Mazor, inks commercial agreement: 6 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
